In the Clinic
Our lead investigational drug, palazestrant (OP-1250), is a novel oral compound developed to completely antagonize the estrogen receptor (ER) and block the ER-mediated cancer cell growth and proliferation signal.
Palazestrant (OP-1250) Pipeline
Target Patient Population
Discovery
Nonclinical
Phase I
Phase II
Phase III
Clinical
Collaboration
ER+/HER2- Metastatic Breast Cancer
2/3 Line Monotherapy
Combo Therapy with CDK 4/6i ribociclib
Combo Therapy with CDK 4/6i palbociclib
Combo Therapy with PI3Ki alpelisib with PIK3CA mutated
Combo Therapy with mTOR inhibitor everolimus
Combo Therapy with CNS metastases
Gynecology — Oncology
Endometrial Cancer(1)
Gynecologic malignancies
OP-3136 KAT6 Pipeline
Target Patient Population
Discovery
Nonclinical
Phase I
Phase II
Phase III
Clinical
Collaboration
ER+/HER2+ Metastatic Breast Cancer/Castrate-Resistant Prostate Cancer
KAT6 Inhibitor (OP-3136)
Discovery Pipeline
Target Patient Population
Discovery
Nonclinical
Phase I
Phase II
Phase III
Clinical
Collaboration
Undisclosed Oncology target